首頁 > 市場調查報告書 > 製藥

癌症

歐洲乳癌治療市場預測至 2030 年 - 區域分析 - 按藥物治療、乳癌類型和配銷通路

市場調查報告書

商品編碼

1481921

歐洲乳癌治療市場預測至 2030 年 - 區域分析 - 按藥物治療、乳癌類型和配銷通路

Europe Breast Cancer Therapeutics Market Forecast to 2030 - Regional Analysis - by Drug Therapy, Breast Cancer Type, and Distribution Channel

出版日期: 2024年03月04日 | 出版商:

The Insight Partners | 英文 106 Pages | 訂單完成後即時交付

價格

簡介目錄圖表

2022年歐洲乳癌治療市值為84.4696億美元，預計到2030年將達到168.3617億美元；預計 2022 年至 2030 年複合年成長率為 9.0%。

政府和私人組織加強支持推動歐洲乳癌治療市場

各國政府認知到解決乳癌問題的重要性，並正在實施政策以改善獲得有效治療的機會。許多政府和私人組織增加了乳癌治療研究和開發的資金，從而促進了創新藥物和療法的開發。歐盟委員會乳癌計劃 (ECIBC) 在各個層面提供普遍可用的基本優質照護。 ECIBC 的使命是根據最新的科學研究，為女性和醫療保健從業者提供有關篩檢和護理的公正、無偏見的建議。研究投資的增加使製藥公司能夠探索新的治療方案，並為乳癌患者開發高度針對性和有效的療法。

世界各地的一些政府機構也正在採取措施，透過實施報銷政策和醫療保健計劃來支付患者乳癌治療的費用，以改善獲得這些治療的機會。這意味著更多的患者能夠負擔得起這些治療，並能夠獲得乳癌治療的最新進展。政府支持力度的加大也為醫療保健提供者創造了有利的市場環境。有了更多的資金和資源，醫療保健提供者就能夠為患者提供更廣泛的治療選擇。這改善了患者的治療效果，並使醫療保健提供者能夠在市場上保持競爭力。總體而言，政府和私人組織對乳癌治療的支持不斷增加，推動了創新，帶來了新的和改進的治療方法。它還改善了獲得這些治療的機會，使更多患者受益。隨著製藥公司和醫療保健提供者繼續投資於研發活動並擴大其產品範圍以滿足不斷成長的需求，這為歐洲乳癌治療市場的成長提供了重大機會。

歐洲乳癌治療市場概況

歐洲乳癌治療市場分為德國、英國、法國、義大利、西班牙和歐洲其他地區。乳癌是英國常見的癌症。根據英國國家醫療服務體系 (NHS) 的資料，大約七分之一的女性在一生中被診斷出罹患乳癌。每年約有 55,000 名女性被診斷出罹患乳癌。

醫療產業對新療法治療乳癌患者的更大需求導致了研發投資的增加，從而推動了市場的成長。 Breast Cancer Now 是英國最大的專門乳癌研究資助機構。迄今為止，它已投資 3.0801 億美元（2.5 億英鎊）進行突破性研究，為乳癌患者開發更好的治療方法。

此外，政府的努力和市場參與者採取的措施有助於加速該國乳癌治療市場的成長。 2022 年 11 月，NHS 透過一項新的藥物交易推出了一種創新且可能挽救生命的乳癌藥物。 Pembrolizumab（Keytruda）與化療結合，可將乳癌進展的幾率降低近五分之二。該藥物每三到六週就會直接進入血液，持續一年多； NHS 資助治療，為符合條件的患者提供治療機會。這是繼 sacituzumab govitecan (Trodelvy) 之後，NHS 提供的第二種治療三陰性乳癌的新藥。

歐洲乳癌治療市場收入及 2030 年預測（百萬美元）

歐洲乳癌治療市場細分

歐洲乳癌治療市場根據藥物治療、乳癌類型和配銷通路進行細分。

根據藥物治療，歐洲乳癌治療市場分為標靶藥物治療、荷爾蒙藥物治療、化療和免疫治療/生物治療。標靶藥物治療細分市場在2022年佔據了更大的佔有率。 emtansine、palbociclib、trastuzumab和其他標靶藥物治療。此外，荷爾蒙藥物治療部分分為選擇性雌激素受體調節劑、芳香酶抑制劑和選擇性雌激素受體下調劑。

就乳癌類型而言，歐洲乳癌治療市場分為荷爾蒙受體乳癌、HER2+乳癌和三陰性乳癌。 2022 年，荷爾蒙受體細分市場將佔據更大佔有率。

依配銷通路，歐洲乳癌治療市場分為醫院藥局、藥局和零售藥局、網路藥局。 2022年，醫院藥局部門將佔據更大的佔有率。

依國家/地區分類，歐洲乳癌治療市場分為德國、法國、英國、義大利、西班牙和歐洲其他地區。 2022 年，英國在歐洲乳癌治療市場佔據主導地位。

禮來公司、衛材有限公司、諾華公司、阿斯特捷利康公司、輝瑞公司、吉利德科學公司、默克公司、梯瓦製藥工業有限公司和安進公司是歐洲乳癌治療市場上的一些領先公司。

Governments of various countries recognize the importance of addressing breast cancer and are implementing policies to improve access to effective treatments. Many governments and private organizations have increased funding for research and development in breast cancer therapeutics, resulting in the development of innovative drugs and therapies. The European Commission Initiative on Breast Cancer (ECIBC) offers universally accessible, basic quality care at all levels. The mission of ECIBC is to give women and healthcare practitioners impartial, unbiased advice on screening and care based on the most recent scientific research. The increased investment in research has allowed pharmaceutical companies to explore new treatment options and develop highly targeted and effective therapies for breast cancer patients.

Several government bodies across the world are also taking steps to improve access to these treatments by implementing reimbursement policies and healthcare initiatives that cover the cost of breast cancer therapeutics for patients. This means that more patients can afford these treatments and have access to the latest advancements in breast cancer therapeutics. The increased government support has also created a favorable market environment for healthcare providers. With more funding and resources available, healthcare providers are able to offer their patients a wider range of treatment options. This improves patient outcomes and allows healthcare providers to stay competitive in the market. Overall, the increased support from governments and private organizations for breast cancer therapeutics has driven innovation, leading to new and improved treatments. It has also improved access to these treatments, benefiting more patients. This presents a significant opportunity for the Europe breast cancer therapeutics market growth as pharmaceutical companies and healthcare providers continue to invest in research and development activities and expand their offerings to meet the growing demand.

Europe Breast Cancer Therapeutics Market Overview

The European breast cancer therapeutics market is segmented into Germany, the UK, France, Italy, Spain, and the Rest of Europe. Breast cancer is a common type of cancer in the UK. As per the National Health Service (NHS), about one in seven women are diagnosed with breast cancer during their lifespan in Great Britain data. Each year, ~55,000 women are diagnosed with breast cancer.

Greater demand from the medical industry to treat breast cancer patients with novel therapeutics has led to greater investment in R&D, fueling the growth of the market. Breast Cancer Now is the largest dedicated breast cancer research funder in the UK. To date, it has invested US$ 308.01 million (£250 million) in ground-breaking research to develop better treatment for breast cancer patients.

Additionally, the efforts of government and initiatives taken by market players have helped accelerate the growth of the breast cancer therapeutics market in the country. In November 2022, NHS rolled out an innovative and potentially life-saving breast cancer drug through a new drug deal. Pembrolizumab (Keytruda), combined with chemotherapy, reduces the chances of breast cancer progressing by almost two-fifths. The drug is delivered directly into the bloodstream every three to six weeks for over one year; the NHS funds the treatment to give access to eligible patients. It is the second new drug for triple-negative breast cancer available on the NHS, after sacituzumab govitecan (Trodelvy).

Europe Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Million)

Europe Breast Cancer Therapeutics Market Segmentation

The Europe breast cancer therapeutics market is segmented based on drug therapy, breast cancer type, and distribution channel.

Based on drug therapy, the Europe breast cancer therapeutics market is segmented into targeted drug therapy, hormonal drug therapy, chemotherapy, and immunotherapy/ biological therapy. The targeted drug therapy segment held a larger share in 2022. The targeted drug therapy segment held a larger share in 2022. The targeted drug therapy segment is further subsegmented into abemaciclib, ado-trastuzumab emtansine, palbociclib, trastuzumab, and other target drug therapy. Additionally, the hormonal drug therapy segment is categorized into selective estrogen receptor modulators, aromatase inhibitors, and selective estrogen receptor downregulators.

In terms of breast cancer type, the Europe breast cancer therapeutics market is segmented into hormone receptor, HER2+, and triple-negative breast cancer. The hormone receptor segment held a larger share in 2022.

By distribution channel, the Europe breast cancer therapeutics market is segmented into hospital pharmacies, drug store and retail pharmacies, and online pharmacies. The hospital pharmacies segment held a larger share in 2022.

Based on country, the Europe breast cancer therapeutics market is categorized into Germany, France, UK, Italy, Spain, and the Rest of Europe. The UK dominated the Europe breast cancer therapeutics market in 2022.

Eli Lilly and Co, Eisai Co Ltd, Novartis AG, AstraZeneca Plc, Pfizer Inc, Gilead Sciences Inc, Merck & Co Inc, Teva Pharmaceutical Industries Ltd, and Amgen Inc are some of the leading companies operating in the Europe breast cancer therapeutics market.

1. Introduction

1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Key Insights

3. Research Methodology

3.1 Coverage
3.2 Secondary Research
3.3 Primary Research

4. Europe Breast Cancer Therapeutics Market - Key Industry Dynamics

4.1 Key Market Drivers
- 4.1.1 Growing Burden of Breast Cancer
- 4.1.2 Launch of Several Diagnostics and Screening Programs
4.2 Key Market Restraints
- 4.2.1 High Cost of Diagnosis and Treatment
4.3 Key Market Opportunities
- 4.3.1 Increased Support from Government and Private Organizations
4.4 Key Future Trends
- 4.4.1 Increasing Use of Personalized Medicine
4.5 Impact Analysis:

5. Breast Cancer Therapeutics Market - Europe Market Analysis

5.1 Europe Breast Cancer Therapeutics Market Revenue (US$ Mn), 2022 - 2030

6. Europe Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 - by Drug Therapy

6.1 Overview
6.2 Europe Breast Cancer Therapeutics Market Revenue Share, by Drug Therapy, 2022 & 2030 (%)
6.3 Targeted Drug Therapy
- 6.3.1 Overview
- 6.3.2 Targeted Drug Therapy: Europe Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  - 6.3.2.1 Europe Breast Cancer Therapeutics Market, by Targeted Drug Therapy, 2020-2030 (US$ Million)
6.4 Hormonal Drug Therapy
- 6.4.1 Overview
- 6.4.2 Hormonal Drug Therapy: Europe Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  - 6.4.2.1 Europe Breast Cancer Therapeutics Market, by Hormonal Drug Therapy, 2020-2030 (US$ Million)
6.5 Chemotherapy
- 6.5.1 Overview
- 6.5.2 Chemotherapy: Europe Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
6.6 Immunotherapy/ Biological Therapy
- 6.6.1 Overview
- 6.6.2 Immunotherapy/ Biological Therapy: Europe Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

7. Europe Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 - by Breast Cancer Type

7.1 Overview
7.2 Europe Breast Cancer Therapeutics Market Revenue Share, by Breast Cancer Type, 2022 & 2030 (%)
7.3 Hormone Receptor
- 7.3.1 Overview
- 7.3.2 Hormone Receptor: Europe Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
7.4 HER2+ (human epidermal growth factor receptor 2)
- 7.4.1 Overview
- 7.4.2 HER2+: Europe Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
7.5 Triple-Negative Breast Cancer
- 7.5.1 Overview
- 7.5.2 Triple-Negative Breast Cancer: Europe Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

8. Europe Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 - by Distribution Channel

8.1 Overview
8.2 Europe Breast Cancer Therapeutics Market Revenue Share, by Distribution Channel, 2022 & 2030 (%)
8.3 Hospital Pharmacies
- 8.3.1 Overview
- 8.3.2 Hospital Pharmacies: Europe Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
8.4 Drug Store and Retail Pharmacies
- 8.4.1 Overview
- 8.4.2 Drug Store and Retail Pharmacies: Europe Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
8.5 Online Pharmacies
- 8.5.1 Overview
- 8.5.2 Online Pharmacies: Europe Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

9. Europe Breast Cancer Therapeutics Market - Country Analysis

9.1 Europe Breast Cancer Therapeutics Market, Revenue and Forecast to 2030
- 9.1.1 Overview
- 9.1.2 Europe Breast Cancer Therapeutics Market, Breakdown, by key Country- Revenue (2022) (US$ Million)
- 9.1.3 Europe Breast Cancer Therapeutics Market, by Country, 2022 and 2030 (%)
  - 9.1.3.1 UK
    - 9.1.3.1.1 UK Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
    - 9.1.3.1.2 UK: Breast Cancer Therapeutics Market, by Drug Therapy, 2020-2030 (US$ Million)
    - 9.1.3.1.2.1 UK: Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
    - 9.1.3.1.2.2 UK: Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
    - 9.1.3.1.3 UK: Breast Cancer Therapeutics Market, by Breast Cancer Type, 2020-2030 (US$ Million)
    - 9.1.3.1.4 UK: Breast Cancer Therapeutics Market, by Distribution Channel, 2020-2030 (US$ Million)
  - 9.1.3.2 Germany
    - 9.1.3.2.1 Germany Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
    - 9.1.3.2.2 Germany: Breast Cancer Therapeutics Market, by Drug Therapy, 2020-2030 (US$ Million)
    - 9.1.3.2.2.1 Germany: Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
    - 9.1.3.2.2.2 Germany: Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
    - 9.1.3.2.3 Germany: Breast Cancer Therapeutics Market, by Breast Cancer Type, 2020-2030 (US$ Million)
    - 9.1.3.2.4 Germany: Breast Cancer Therapeutics Market, by Distribution Channel, 2020-2030 (US$ Million)
  - 9.1.3.3 France
    - 9.1.3.3.1 France Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
    - 9.1.3.3.2 France: Breast Cancer Therapeutics Market, by Drug Therapy, 2020-2030 (US$ Million)
    - 9.1.3.3.2.1 France: Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
    - 9.1.3.3.2.2 France: Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
    - 9.1.3.3.3 France: Breast Cancer Therapeutics Market, by Breast Cancer Type, 2020-2030 (US$ Million)
    - 9.1.3.3.4 France: Breast Cancer Therapeutics Market, by Distribution Channel, 2020-2030 (US$ Million)
  - 9.1.3.4 Italy
    - 9.1.3.4.1 Italy Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
    - 9.1.3.4.2 Italy: Breast Cancer Therapeutics Market, by Drug Therapy, 2020-2030 (US$ Million)
    - 9.1.3.4.2.1 Italy: Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
    - 9.1.3.4.2.2 Italy: Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
    - 9.1.3.4.3 Italy: Breast Cancer Therapeutics Market, by Breast Cancer Type, 2020-2030 (US$ Million)
    - 9.1.3.4.4 Italy: Breast Cancer Therapeutics Market, by Distribution Channel, 2020-2030 (US$ Million)
  - 9.1.3.5 Spain
    - 9.1.3.5.1 Spain Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
    - 9.1.3.5.2 Spain: Breast Cancer Therapeutics Market, by Drug Therapy, 2020-2030 (US$ Million)
    - 9.1.3.5.2.1 Spain: Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
    - 9.1.3.5.2.2 Spain: Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
    - 9.1.3.5.3 Spain: Breast Cancer Therapeutics Market, by Breast Cancer Type, 2020-2030 (US$ Million)
    - 9.1.3.5.4 Spain: Breast Cancer Therapeutics Market, by Distribution Channel, 2020-2030 (US$ Million)
  - 9.1.3.6 Rest of Europe
    - 9.1.3.6.1 Rest of Europe Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
    - 9.1.3.6.2 Rest of Europe: Breast Cancer Therapeutics Market, by Drug Therapy, 2020-2030 (US$ Million)
    - 9.1.3.6.2.1 Rest of Europe: Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
    - 9.1.3.6.2.2 Rest of Europe: Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
    - 9.1.3.6.3 Rest of Europe: Breast Cancer Therapeutics Market, by Breast Cancer Type, 2020-2030 (US$ Million)
    - 9.1.3.6.4 Rest of Europe: Breast Cancer Therapeutics Market, by Distribution Channel, 2020-2030 (US$ Million)

10. Breast Cancer Therapeutics Market-Industry Landscape

10.1 Overview
10.2 Growth Strategies in Breast Cancer Therapeutics Market
10.3 Organic Growth Strategies
- 10.3.1 Overview
10.4 Inorganic Growth Strategies
- 10.4.1 Overview

11. Company Profiles

11.1 Eli Lilly and Co
- 11.1.1 Key Facts
- 11.1.2 Business Description
- 11.1.3 Products and Services
- 11.1.4 Financial Overview
- 11.1.5 SWOT Analysis
- 11.1.6 Key Developments
11.2 Eisai Co Ltd
- 11.2.1 Key Facts
- 11.2.2 Business Description
- 11.2.3 Products and Services
- 11.2.4 Financial Overview
- 11.2.5 SWOT Analysis
- 11.2.6 Key Developments
11.3 Novartis AG
- 11.3.1 Key Facts
- 11.3.2 Business Description
- 11.3.3 Products and Services
- 11.3.4 Financial Overview
- 11.3.5 SWOT Analysis
- 11.3.6 Key Developments
11.4 AstraZeneca Plc
- 11.4.1 Key Facts
- 11.4.2 Business Description
- 11.4.3 Products and Services
- 11.4.4 Financial Overview
- 11.4.5 SWOT Analysis
- 11.4.6 Key Developments
11.5 Pfizer Inc
- 11.5.1 Key Facts
- 11.5.2 Business Description
- 11.5.3 Products and Services
- 11.5.4 Financial Overview
- 11.5.5 SWOT Analysis
- 11.5.6 Key Developments
11.6 Gilead Sciences Inc
- 11.6.1 Key Facts
- 11.6.2 Business Description
- 11.6.3 Products and Services
- 11.6.4 Financial Overview
- 11.6.5 SWOT Analysis
- 11.6.6 Key Developments
11.7 Merck & Co Inc
- 11.7.1 Key Facts
- 11.7.2 Business Description
- 11.7.3 Products and Services
- 11.7.4 Financial Overview
- 11.7.5 SWOT Analysis
- 11.7.6 Key Developments
11.8 Teva Pharmaceutical Industries Ltd
- 11.8.1 Key Facts
- 11.8.2 Business Description
- 11.8.3 Products and Services
- 11.8.4 Financial Overview
- 11.8.5 SWOT Analysis
- 11.8.6 Key Developments
11.9 Amgen Inc
- 11.9.1 Key Facts
- 11.9.2 Business Description
- 11.9.3 Products and Services
- 11.9.4 Financial Overview
- 11.9.5 SWOT Analysis
- 11.9.6 Key Developments

12. Appendix

12.1 About Us
12.2 Glossary of Terms

簡介目錄圖表

List Of Tables

Table 1. Europe Breast Cancer Therapeutics Market Segmentation
Table 2. Europe Breast Cancer Therapeutics Market, by Targeted Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
Table 3. Europe Breast Cancer Therapeutics Market, by Hormonal Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
Table 4. UK Breast Cancer Therapeutics Market, by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
Table 5. UK Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
Table 6. UK Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
Table 7. UK Breast Cancer Therapeutics Market, by Breast Cancer Type - Revenue and Forecast to 2030 (US$ Million)
Table 8. UK Breast Cancer Therapeutics Market, by Distribution Channel - Revenue and Forecast to 2030 (US$ Million)
Table 9. Germany Breast Cancer Therapeutics Market, by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
Table 10. Germany Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
Table 11. Germany Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
Table 12. Germany Breast Cancer Therapeutics Market, by Breast Cancer Type - Revenue and Forecast to 2030 (US$ Million)
Table 13. Germany Breast Cancer Therapeutics Market, by Distribution Channel - Revenue and Forecast to 2030 (US$ Million)
Table 14. France Breast Cancer Therapeutics Market, by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
Table 15. France Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
Table 16. France Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
Table 17. France Breast Cancer Therapeutics Market, by Breast Cancer Type - Revenue and Forecast to 2030 (US$ Million)
Table 18. France Breast Cancer Therapeutics Market, by Distribution Channel - Revenue and Forecast to 2030 (US$ Million)
Table 19. Italy Breast Cancer Therapeutics Market, by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
Table 20. Italy Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
Table 21. Italy Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
Table 22. Italy Breast Cancer Therapeutics Market, by Breast Cancer Type - Revenue and Forecast to 2030 (US$ Million)
Table 23. Italy Breast Cancer Therapeutics Market, by Distribution Channel - Revenue and Forecast to 2030 (US$ Million)
Table 24. Spain Breast Cancer Therapeutics Market, by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
Table 25. Spain Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
Table 26. Spain Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
Table 27. Spain Breast Cancer Therapeutics Market, by Breast Cancer Type - Revenue and Forecast to 2030 (US$ Million)
Table 28. Spain Breast Cancer Therapeutics Market, by Distribution Channel - Revenue and Forecast to 2030 (US$ Million)
Table 29. Rest of Europe Breast Cancer Therapeutics Market, by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
Table 30. Rest of Europe Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
Table 31. Rest of Europe Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
Table 32. Rest of Europe Breast Cancer Therapeutics Market, by Breast Cancer Type - Revenue and Forecast to 2030 (US$ Million)
Table 33. Rest of Europe Breast Cancer Therapeutics Market, by Distribution Channel - Revenue and Forecast to 2030 (US$ Million)
Table 34. Recent Organic Growth Strategies in Breast Cancer Therapeutics Market
Table 35. Recent Inorganic Growth Strategies in the Breast Cancer Therapeutics Market
Table 36. Glossary of Terms, Breast Cancer Therapeutics Market

List Of Figures

Figure 1. Europe Breast Cancer Therapeutics Market Segmentation, By Country
Figure 2. Europe Breast Cancer Therapeutics Market - Key Industry Dynamics
Figure 3. Impact Analysis of Drivers and Restraints
Figure 4. Europe Breast Cancer Therapeutics Market Revenue (US$ Mn), 2022 - 2030
Figure 5. Europe Breast Cancer Therapeutics Market Revenue Share, by Drug Therapy, 2022 & 2030 (%)
Figure 6. Targeted Drug Therapy: Europe Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 7. Hormonal Drug Therapy: Europe Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 8. Chemotherapy: Europe Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 9. Immunotherapy/ Biological Therapy: Europe Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 10. Europe Breast Cancer Therapeutics Market Revenue Share, by Breast Cancer Type, 2022 & 2030 (%)
Figure 11. Hormone Receptor: Europe Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 12. HER2+: Europe Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 13. Triple-Negative Breast Cancer: Europe Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 14. Europe Breast Cancer Therapeutics Market Revenue Share, by Distribution Channel, 2022 & 2030 (%)
Figure 15. Hospital Pharmacies: Europe Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 16. Drug Store and Retail Pharmacies: Europe Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 17. Online Pharmacies: Europe Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 18. Europe Breast Cancer Therapeutics Market, by Key Country - Revenue (2022) (US$ Million)
Figure 19. Europe Breast Cancer Therapeutics Market, By Key Countries, 2022 and 2030 (%)
Figure 20. UK Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
Figure 21. Germany Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
Figure 22. France Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
Figure 23. Italy Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
Figure 24. Spain Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
Figure 25. Rest of Europe Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
Figure 26. Growth Strategies in Breast Cancer Therapeutics Market